NEW YORK (GenomeWeb News) – AB Sciex and Alturas Analytics today announced a deal combining technologies from both firms to drive adoption of dried blood spot analysis for drug discovery and development.
Under the terms of the deal, Alturas scientists will use AB Sciex's QTrap 5500 mass spectrometry platform and novel microflow chromatography technology from AB Sciex's Eksigent business to build out workflows for dried blood spot analysis.
Dried blood spot analysis can help pharmaceutical firms save money and increase productivity by streamlining the collection, storage, and shipment of samples from preclinical and clinical studies in the drug development process, the two companies said. They added that when compared to traditional bioanalysis methods, the technique requires few animals during preclinical trials and less blood drawn during clinical trials.
"With this approach, scientists can obtain the same or better information than currently possible with traditional sampling techniques," AB Sciex and Alturas said in a statement.
Alturas, a provider of liquid chromatography-mass spectrometry contract research services, is developing workflows using MRM
Shane Needham, laboratory director for Alturas, said that the company's dried blood spot technique can be used for other matrixes as well, including urine, plasma, and tears.
Financial and other terms of the deal were not disclosed.